Entities / Company
Amgen.
American multinational biopharmaceutical company
- Reports this week
- 13
- Active events
- 15
- Connections
- 478
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Active this week
-
Amgen, City of Hope, and the California Community Foundation are involved in a life sciences and bioscience economic summit held in Downtown Los Angeles.Some support1 report
-
Geode Capital Management increased its stake in Amgen stock and filed the disclosure with the SEC.Some support2 reports
-
AI stocks are benefiting from Trump-era tariffs, with Morningstar and ClearBridge providing market analysis on growth and upside potential.Some support13 reports10 developments inside
-
Trump's oil and gas pledges benefit US stocks, specifically impacting Pfizer.Well supported131 reports40 developments inside
-
Intuit provides financial management services including TurboTax, Mailchimp, and Credit Karma, alongside developing innovative medicines.Well supported10 reports1 development inside
-
Royalty Pharma acquired a royalty interest in Amgen's drug Imdelltra.Well supported9 reports
-
Trump's tariff plan caused markets to tank, affecting company Flo.Some support79 reports12 developments inside
-
Amgen Inc. trades on the NASDAQ stock exchange.Well supported21 reports
-
Pharmaceutical companies are adopting AI for clinical data gathering, product promotion, and prototyping.Well supported4 reports12 developments inside
-
The EPA recognized Amgen's green chemistry efforts, involving VP Margaret Faul, who previously worked at Eli Lilly.Some support1 report
-
Sanofi removed Sjögren's from frexalimab and Novartis discontinued iscalimab in Sjögren's.Some support1 report
-
RFK Jr.'s appointment as HHS Secretary is creating pressure as Medicare price setting and Part D redesign impact the sales and operations of major pharmaceutical companies including Pfizer, Amgen, J&J, Merck, and Eli Lilly.Speculative1 report2 developments inside
-
Amgen and Deloitte are cited as examples of companies undergoing industry transformation.Some support1 report
-
Amgen acquired Horizon Therapeutics, a company whose portfolio included a drug discovered by AstraZeneca.Some support1 report
-
Berkshire Hathaway disclosed a large share purchase of Amgen on September 22, 2026.Some support1 report
Earlier this month
-
Pfizer, Merck, and Amgen are large-cap drugmakers with significant operations in the United States.Some support1 report1 development inside
-
Amgen and Merck are currently competing against each other in the market for investor capital.Some support3 reports
-
Several biotech companies reported clinical trial setbacks, including Argenx and Immunovant, while Sling Therapeutics' drug was compared to offerings from Viridian and Amgen.Some support1 report
-
Both Amdocs and Amgen are currently subject to analyst reviews.Some support1 report
-
Multiple companies, including Eli Lilly, Amgen, Ionis, and Novartis, are developing advanced experimental drugs for heart disease, including those targeting Lp(a).Some support2 reports7 developments inside
-
Analyst upgrades and downgrades are affecting the stock performance of Amgen and CF Industries.Some support1 report
-
Amgen and Novartis have developed similar drugs aimed at treating heart conditions.Some support6 reports2 developments inside
-
A rival's trial failure has challenged the shared scientific hypothesis between Amgen and Novartis.Some support1 report
-
Novartis' drug failure has negatively impacted Amgen's financial outlook.Some support2 reports1 development inside
-
The market is reacting to the news of Novartis' drug trial failures, specifically impacting Amgen's stock performance on the Nasdaq exchange.Some support2 reports
-
Amgen discusses biotech and pharma trends with Wells Fargo, where Thomas Dittrich serves as the company's Chief Financial Officer.Some support1 report
-
Cantor Fitzgerald and other analyst firms issued ratings on Amgen stock, which is listed on the Nasdaq exchange.Some support1 report
-
Barclays raises S&P 500 target, Amgen stock slumps after trial failure, and oil prices rise due to escalating Middle East hostilities.Some support1 report
-
Novartis and Amgen stocks are declining, putting pressure on the Dow Jones Industrial Average due to their shared focus on cholesterol-targeting drugs.Some support1 report
-
Reports on the top holdings of various healthcare and biotech ETFs, listing major pharmaceutical companies like Eli Lilly, Amgen, and Johnson & Johnson.Some support1 report
-
Amgen and AstraZeneca partnered on a Phase 3 CROSSING trial for the drug TEZSPIRE.Some support3 reports1 development inside
-
Amgen and AstraZeneca co-developed the severe asthma drug TEZSPIRE, prompting an analyst to raise the price target.Some support2 reports
-
Amgen's stock price was impacted by clinical trial disappointments, while Brent crude influenced S&P 500 market movement.Some support1 report
-
Amgen and AstraZeneca announced a collaborative development of a combination therapy.Some support2 reports1 development inside
-
Joint drug trial success boosts Amgen stock.Some support1 report
-
Geopolitical risk drives energy prices due to Iranian regime action, while clinical failures impact biotech stocks and Dell Technologies gains investor favor.Some support1 report
-
GSK and Amgen are major biopharma players.Some support1 report
-
Amgen and Eli Lilly offer treatments for thyroid eye disease, with Lilly's pipeline requiring regulatory approval.Some support6 reports1 development inside
-
The biotech sector is experiencing a downturn due to drug failures, impacting companies like Amgen and Eli Lilly.Some support1 report
-
Market activity was monitored by representatives involving Amgen and Broadcom.Some support3 reports
-
Amgen benefits from Novartis/Ionis Phase 3 research, Mizuho raised price targets, and the company faces a tax dispute resolution timeline.Some support4 reports
-
Both Microsoft and Amgen are major dividend payers currently under market scrutiny.Some support1 report1 development inside
-
Amgen and Microsoft are top holdings in an ETF.Some support1 report
-
Norges Bank, Cantor Fitzgerald, Bank of America, and Scotiabank announced new stakes and target price boosts for Amgen.Some support1 report
-
Amgen presented findings at the European Society of Cardiology Congress in Munich.Some support1 report
One to three months ago
-
Amgen filed required reports with the Securities and Exchange Commission on June 16, 2026.Some support4 reports1 development inside
-
Mikey Taylor graduated from Newbury Park High School and is running for Thousand Oaks City Council, while Karen Arreola worked at Amgen.Some support1 report
-
Healthcare stocks surged to record highs on August 19, 2026, amid market excitement over drug breakthroughs involving Moderna, Amgen, and Merck.Some support2 reports
-
Amgen is reportedly interested in BioCryst Pharmaceuticals, which operates in the rare-disease market, as a potential acquisition target.Some support1 report
-
Amgen launches a research program in India.Some support6 reports1 development inside
-
Amgen plans to open a new Science and Innovation Center and major R&D hub in Hyderabad.Some support16 reports
-
Rating changes were reported for several companies on August 8, 2026, including upgrades from hold to buy and sell to hold.Some support1 report
-
Ligand Pharmaceuticals formed drug development partnerships with Amgen, Merck KGaA, and Pfizer.Some support2 reports2 developments inside
-
A company whose founders were former Amgen employees is listing shares on an exchange as part of a renewed biotech IPO wave.Some support1 report
-
A company, likely Amgen or Generate Biomedicines Inc, is leveraging the Chroma model for an AI platform, backed by co-development deals.Some support1 report
-
Abbott Laboratories and Amgen are major holdings in the SCHD ETF.Some support1 report
-
Market gains for Amgen, Nvidia, and Disney shares, alongside talks regarding the re-opening of the Strait of Hormuz.Some support1 report
-
Novavax, Nvidia, Biogen, and Amgen are involved in developments regarding specialized infrastructure and their shared status as peers in the therapeutics segment.Some support2 reports
-
Norges Bank acquired a new stake in Amgen, which is listed on Nasdaq and subject to required filings with the Securities and Exchange Commission.Some support2 reports1 development inside
-
Norges Bank acquired a new stake in Amgen shares, and Amundi boosted its position in the company.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around Amgen this week
News at the entities that move Amgen most-
FDA StructuralGeneric medicine services are seeking approval for launch from the FDA.Moves Amgen
-
Norges Bank TransactionalNorges Bank bought a new position in Qualcomm shares, coinciding with buy ratings and price targets from TD Cowen, reported by MarketBeat.Moves Amgen
-
SEC StructuralDHS, DOJ, and SEC formed a joint initiative to establish a Trade Fraud Task Force, setting standards for compliance.Moves Amgen
-
Quantinuum StructuralMarketBeat features a stock screener that allows users to track various companies.Moves Amgen
-
Colorado StructuralThree separate events occurred on August 28, 2026: a Leon County grand jury report, a Colorado pardon by Polis, and alleged misuse of funds by DeSantis.Moves Amgen
-
Securities and Exchange Commission StructuralBlackRock, the manager of the iShares Core MSCI EAFE ETF, has made required filings with the Securities and Exchange Commission regarding institutional holdings.Moves Amgen
Connections
The 40 strongest of 478, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Novartis Operational
Amgen and Novartis are direct competitors in the biopharmaceutical market, where clinical trial outcomes and market events of one significantly impact the other's stock performance and risk profile.
-
Norges Bank Transactional
Norges Bank purchased a new stake in Amgen stock.
-
Jyothis George Structural
Jyothis George held a Global Medical Vice President role at Amgen and drove strategic decision making for the company.
-
Nasdaq Structural
Amgen is a publicly traded company whose listing and trading are formally hosted on the NASDAQ stock exchange.
-
Genome Valley Structural
Amgen is establishing a dedicated Science and Innovation Center within the Genome Valley ecosystem.
-
Novo Nordisk Operational
Amgen and Novo Nordisk are direct competitors in the GLP-1 and obesity drug markets.
-
Thomas Dittrich Structural
Thomas Dittrich serves as the Chief Financial Officer of Amgen.
-
Horizon Therapeutics Structural
Amgen acquired Horizon Therapeutics, making it a subsidiary and integrating its rare disease portfolio.
Show all 40 connections
-
SEC Structural
Amgen operates under the formal financial reporting and disclosure requirements mandated by the SEC.
-
Jay Bradner Structural
Jay Bradner holds an executive vice president role in R&D at Amgen.
-
Onyx Pharmaceuticals Structural
Amgen acquired Onyx Pharmaceuticals for $10 billion, establishing a parent-subsidiary relationship.
-
Morgan Stanley Operational
Morgan Stanley actively monitors Amgen's clinical data and issues research reports, influencing its market valuation and price targets.
-
Cencora Structural
Amgen relies on Cencora as a critical distributor and wholesaler for its pharmaceutical products.
-
Eli Lilly and Company Operational
Both companies are direct competitors in advanced drug markets, specializing in GLP-1 agonists, obesity treatments, and Lp(a) reduction.
-
FDA Structural
The FDA formally regulates Amgen's drug development, approval, and market use, dictating its operational scope.
-
Cardinal Health Structural
Amgen relies on Cardinal Health as a critical partner for product distribution and revenue concentration.
-
Johnson & Johnson Operational
Johnson & Johnson and Amgen are active competitors in the biopharma sector, vying for market leadership in immunology and bispecific antibodies.
-
Royalty Pharma Structural
Royalty Pharma holds royalty rights to Amgen's drugs, establishing a persistent financial dependency on Amgen's sales.
-
Quantinuum Structural
Amgen utilizes Quantinuum's quantum computing platform as a critical component for its advanced operations.
-
Colorado Structural
Colorado state regulators impose price caps and affordability board actions on Amgen's drug products.
-
Robert A. Bradway Operational
Robert A. Bradway serves as the CEO and Chairman of Amgen, actively leading its performance.
-
Pfizer Operational
Pfizer and Amgen are major pharmaceutical competitors actively developing and marketing treatments in specialized markets like weight loss, biosimilars, and thyroid care.
-
Veeva Systems Structural
Veeva provides clinical trial and CRM platforms that Amgen utilizes for operational efficiencies and collaboration.
-
Invesco Structural
Invesco holds a large, persistent investment position in Amgen stock.
-
Margaret Faul Structural
Margaret Faul is employed as a Vice President at Amgen.
-
Peter Griffith Structural
Peter Griffith serves as the Chief Financial Officer (CFO) of Amgen.
-
Securities and Exchange Commission Structural
Amgen is subject to mandatory regulatory filings and oversight by the Securities and Exchange Commission.
-
Pirow Bekker Transactional
Amgen acquired ChemoCentryx, the company that employed Pirow Bekker.
-
Merck Operational
Amgen and Merck are direct competitors in the biosimilar market, large-cap drug sector, and for investor capital.
-
MCK Structural
MCK functions as a key distributor and wholesaler for Amgen, upon which Amgen relies for revenue concentration.
-
Donald Trump Operational
Trump leverages his political influence and policy proposals, including tariff threats and specific agreements, to impact Amgen's market operations and business outlook.
-
David Reese Structural
David Reese holds a senior executive role (EVP & CTO) at Amgen, demonstrating deep functional integration.
-
Medicare Structural
Medicare regulates Amgen's pricing and sets benchmarks for drug costs under the Inflation Reduction Act.
-
Astellas Pharma Operational
Amgen and Astellas Pharma engage in strategic collaborations.
-
Sanofi Operational
Sanofi and Amgen are direct competitors operating in the biopharma sector, vying for market leadership in dyslipidemia treatment.
-
AbbVie Operational
AbbVie and Amgen are direct competitors in the biopharmaceutical sector, particularly in the psoriatic arthritis market.
-
Mizuho Transactional
Mizuho published a report that raised its price objective for Amgen, representing a specific market assessment of Amgen's value.
-
Scotiabank Operational
Scotiabank provides analyst support and target price recommendations for Amgen.
-
Ligand Pharmaceuticals Operational
Ligand Pharmaceuticals and Amgen maintain an ongoing partnership for drug development.
-
Amundi Transactional
Amundi increased its investment stake in Amgen shares.
History
Events by the month they beganSeptember 2026
30 events- Amgen, City of Hope, and the California Community Foundation are involved in a life sciences and bioscience economic summit held in Downtown Los Angeles.
- The EPA recognized Amgen's green chemistry efforts, involving VP Margaret Faul, who previously worked at Eli Lilly.
- Sanofi removed Sjögren's from frexalimab and Novartis discontinued iscalimab in Sjögren's.
- Amgen and Deloitte are cited as examples of companies undergoing industry transformation.
- Amgen acquired Horizon Therapeutics, a company whose portfolio included a drug discovered by AstraZeneca.
- Berkshire Hathaway disclosed a large share purchase of Amgen on September 22, 2026.
- Amgen and Merck are currently competing against each other in the market for investor capital.
- Several biotech companies reported clinical trial setbacks, including Argenx and Immunovant, while Sling Therapeutics' drug was compared to offerings from Viridian and Amgen.
- Both Amdocs and Amgen are currently subject to analyst reviews.
- Analyst upgrades and downgrades are affecting the stock performance of Amgen and CF Industries.
- Amgen and Novartis have developed similar drugs aimed at treating heart conditions.
- A rival's trial failure has challenged the shared scientific hypothesis between Amgen and Novartis.
- Novartis' drug failure has negatively impacted Amgen's financial outlook.
- The market is reacting to the news of Novartis' drug trial failures, specifically impacting Amgen's stock performance on the Nasdaq exchange.
- Amgen discusses biotech and pharma trends with Wells Fargo, where Thomas Dittrich serves as the company's Chief Financial Officer.
- Cantor Fitzgerald and other analyst firms issued ratings on Amgen stock, which is listed on the Nasdaq exchange.
- Barclays raises S&P 500 target, Amgen stock slumps after trial failure, and oil prices rise due to escalating Middle East hostilities.
- Novartis and Amgen stocks are declining, putting pressure on the Dow Jones Industrial Average due to their shared focus on cholesterol-targeting drugs.
- Reports on the top holdings of various healthcare and biotech ETFs, listing major pharmaceutical companies like Eli Lilly, Amgen, and Johnson & Johnson.
- Amgen and AstraZeneca co-developed the severe asthma drug TEZSPIRE, prompting an analyst to raise the price target.
- Amgen's stock price was impacted by clinical trial disappointments, while Brent crude influenced S&P 500 market movement.
- Amgen and AstraZeneca announced a collaborative development of a combination therapy.
- Joint drug trial success boosts Amgen stock.
- Geopolitical risk drives energy prices due to Iranian regime action, while clinical failures impact biotech stocks and Dell Technologies gains investor favor.
- GSK and Amgen are major biopharma players.
- The biotech sector is experiencing a downturn due to drug failures, impacting companies like Amgen and Eli Lilly.
- Market activity was monitored by representatives involving Amgen and Broadcom.
- Amgen and Microsoft are top holdings in an ETF.
- Norges Bank, Cantor Fitzgerald, Bank of America, and Scotiabank announced new stakes and target price boosts for Amgen.
- Amgen presented findings at the European Society of Cardiology Congress in Munich.
August 2026
15 events- Pfizer, Merck, and Amgen are large-cap drugmakers with significant operations in the United States.
- Amgen and AstraZeneca partnered on a Phase 3 CROSSING trial for the drug TEZSPIRE.
- Amgen and Eli Lilly offer treatments for thyroid eye disease, with Lilly's pipeline requiring regulatory approval.
- Both Microsoft and Amgen are major dividend payers currently under market scrutiny.
- Mikey Taylor graduated from Newbury Park High School and is running for Thousand Oaks City Council, while Karen Arreola worked at Amgen.
- Healthcare stocks surged to record highs on August 19, 2026, amid market excitement over drug breakthroughs involving Moderna, Amgen, and Merck.
- Amgen is reportedly interested in BioCryst Pharmaceuticals, which operates in the rare-disease market, as a potential acquisition target.
- Amgen plans to open a new Science and Innovation Center and major R&D hub in Hyderabad.
- Rating changes were reported for several companies on August 8, 2026, including upgrades from hold to buy and sell to hold.
- A company whose founders were former Amgen employees is listing shares on an exchange as part of a renewed biotech IPO wave.
- A company, likely Amgen or Generate Biomedicines Inc, is leveraging the Chroma model for an AI platform, backed by co-development deals.
- Abbott Laboratories and Amgen are major holdings in the SCHD ETF.
- Market gains for Amgen, Nvidia, and Disney shares, alongside talks regarding the re-opening of the Strait of Hormuz.
- Novavax, Nvidia, Biogen, and Amgen are involved in developments regarding specialized infrastructure and their shared status as peers in the therapeutics segment.
- Norges Bank acquired a new stake in Amgen shares, and Amundi boosted its position in the company.
July 2026
3 events- Amgen benefits from Novartis/Ionis Phase 3 research, Mizuho raised price targets, and the company faces a tax dispute resolution timeline.
- Amgen launches a research program in India.
- Norges Bank acquired a new stake in Amgen, which is listed on Nasdaq and subject to required filings with the Securities and Exchange Commission.
Show 1 earlier month
June 2026
12 events- Geode Capital Management increased its stake in Amgen stock and filed the disclosure with the SEC.
- AI stocks are benefiting from Trump-era tariffs, with Morningstar and ClearBridge providing market analysis on growth and upside potential.
- Trump's oil and gas pledges benefit US stocks, specifically impacting Pfizer.
- Intuit provides financial management services including TurboTax, Mailchimp, and Credit Karma, alongside developing innovative medicines.
- Royalty Pharma acquired a royalty interest in Amgen's drug Imdelltra.
- Trump's tariff plan caused markets to tank, affecting company Flo.
- Amgen Inc. trades on the NASDAQ stock exchange.
- Pharmaceutical companies are adopting AI for clinical data gathering, product promotion, and prototyping.
- RFK Jr.'s appointment as HHS Secretary is creating pressure as Medicare price setting and Part D redesign impact the sales and operations of major pharmaceutical companies including Pfizer, Amgen, J&J, Merck, and Eli Lilly.
- Multiple companies, including Eli Lilly, Amgen, Ionis, and Novartis, are developing advanced experimental drugs for heart disease, including those targeting Lp(a).
- Amgen filed required reports with the Securities and Exchange Commission on June 16, 2026.
- Ligand Pharmaceuticals formed drug development partnerships with Amgen, Merck KGaA, and Pfizer.